

Hutchison MediPharma - R&D pipeline

■ ONCOLOGY ■ AUTOIMMUNE

DISCOVERY	Lead Generation	Lead Optimisation	Exploratory Candidate	Preclinical Tox & CMC	
HMPL-010 (Autoimmune Disease)					HMPL-010 - Cytokine inhibitor for psoriasis.
HMPL-011 (Inflammation)					Novel series of cytokine modulators - Demonstrated good efficacy in rheumatoid arthritis in animal models and pharmacokinetic properties. Entering prelim safety evaluation.
Kinase (Cancer)					Multi-kinase inhibitor project - Patent applications filed. In-vitro activity and efficacy in animal models of tumour growth. Two new cancer projects - In lead generation stage.
Kinase (Inflammation / pulmonary)					Kinase inhibitor project - Targeting inflammation asthma at lead optimisation stage.
DEVELOPMENT	Preclinical Tox & CMC	Phase I	Phase II	Phase III	
HMPL-004(US) (Crohn's disease)					ON TRACK - 50% of patients enrolled.
HMPL-004(Global) (Ulcerative colitis)					NEW IND/TRIAL - FDA approved global multi-centre phase IIb trial in 10-07 based on China phase II POC success.
HMPL-002(US) (Head & neck cancer)					ON TRACK - First cohort of the phase I trial completed with no drug related severe adverse events. Second and final dose cohort started July-07. Phase II start 2008.
HMPL-002(PRC) (Non small cell lung cancer)					ON TRACK - 100% of patients enrolled. 6-month survival interim release 2008.